[1] 李剑萍,陈学福,严勤,等.索磷布韦维帕他韦联合或不联合利巴韦林治疗中国成人慢性丙型肝炎病毒感染者的疗效和安全性.中华肝脏病杂志,2020,28(10):831-837. [2] Kandeel A, Genedy M, El-Refai S, et al. The prevalence of hepatitis Cvirus infection in Egypt 2015: implications for future policy onprevention and treatment. Liver Int, 2017, 37(1):45-53. [3] 曾庆磊,吕君,付艳玲,等.慢性丙型肝炎经抗病毒治疗后获得持续病毒学应答患者发生肝细胞癌危险因素预测分析.中华传染病杂志,2016,34(3):160-165. [4] 向光明,黄孝伦,姚豫桐,等.慢性丙型肝炎相关性肝细胞癌患者根治性外科干预后使用干扰素的Meta分析.中华肝胆外科杂志,2016,22(12):805-809. [5] Toshikuni N. Therapy with direct-acting antiviral agents for hepatitis C-related liver cirrhosis. Gut Liver, 2017, 11(3):335-348. [6] Kaku A. FIB-4 stage of liver fibrosis predicts incident heart failureamong HIV-infected and uninfected patients. Hepatology, 2017, 66(4):1286-1295. [7] 中华医学会肝病学分会和感染病学分会.《丙型肝炎防治指南》2019年更新版.实用肝脏病杂志,2020,23(1):S33-52. [8] Eldesoky E S,Abdelhafez A T,Cusato J,et al. The role of itpa and ribavirin transporter genes polymorphisms in prediction of ribavirin-induced anaemia in chronic hepatitis C Egyptian patients. Clin Exp Pharmacol Physiol, 2017, 44(9 ):965-968. [9] Roncero C, Littlewood R, Vega P, et al. Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment,challenges for successful treatment. Eur J Gastroenterol Hepatol, 2017, 29(6): 629-633. [10] Hung H C,Liao H H,ChenSC,et al. Maintenance interferon therapy in chronic hepatitis C patients who failed initial antiviral therapy: a meta-analysis. Medicine (Baltimore ), 2019, 98(19):15563-15564. [11] Wang S, Qin E, Zhi Y, et al. Severe autoimmune hemolytic anemia during pegylated interferon plus ribavirin treatment for chronic hepatitis C: a case report. Clin Case Rep, 2017, 5(9): 1490-1492. [12] Tabernilla A, Grandal M, Pernas B, et al.Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration. Eur J Gastroenterol Hepatol, 2017, 29(7):781-785. [13] El-Khayat H, Fouad Y, Mohamed HI, et al. Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4. Aliment Pharmacol Ther, 2018, 47(5):674-679. [14] Boglione L,Pinna SM,Cardellino CS, et al. Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation prolease inhibitors. Infection, 2017, 45(1):103-106. [15] Tseng T C,Liu CJ,Su T H,et al. Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection. Aliment Pharmacol Ther, 2018, 47(11 ):1480-1489. [16] Wang W,Zhao X, Li G, et al. Diagnostic thresholds and performance of noninvasive fibrosis scores are limited by age in patients with chronic hepatitis B. J Med Virol, 2019, 91(7):1279-1287. [17] Butt A A, Ren Y, Re V L,et al. Comparing Child-Pugh, MELD and FIB-4 to predict clinical outcomes in CHC-infected persons: Results from ERCHIVES. Clin Infect Dis, 2017, 65(1):64-72. [18] Boglione L, Mornese PS, De NA, et al. Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users:aprospective study. J Viral Hepat, 2017, 24(10):850-785. |